Gastric Cancer: Pathogenesis, Screening, and Treatment

Sugano, Kentaro

doi:10.1016/j.giec.2008.05.003

Cited by 31 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This figure contrasts significantly with those reported from Spain (20%) and Japan (53%). 24,25 Hence, measures to further improve the early diagnosis of upper gastrointestinal malignancies are needed. Key personnel to perform ESD in individual hospitals should be identified and receive intensive training in screening endoscopy to improve detection of early lesions.…”

Section: Discussionmentioning

confidence: 99%

Hospital Authority audit of the outcome of endoscopic resection of superficial upper gastro-intestinal lesions in Hong Kong

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Hospital Authority audit of the outcome of endoscopic resection of superficial upper gastro-intestinal lesions in Hong Kong

et al. 2015

View full text Add to dashboard Cite

“…Despite some advances were achieved in the treatment of advanced gastric cancer (Sipponen 2002;Fukase et al 2008;Lee et al 2008;Sugano 2008), these patients still do poorly. Radical surgical resection is still the best treatment option in clinical practice (Lynch et al 2008).…”

Section: Discussionmentioning

confidence: 99%

Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer

Wang

Song

Liu

et al. 2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Although surgery is appropriate for patients with resectable disease, most GC patients present with locally advanced or metastatic disease which is not amenable for radical surgery [4]. Multimodality treatment with neoadjuvant or adjuvant regional and systemic therapies is now a standard of care but despite the integration of combined therapies, overall survival remains low with 5-year survival rates of 30–36% [5,6].…”

Section: Introductionmentioning

confidence: 99%

Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy

Cidon

Ellis

Inam

et al. 2013

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) represents a major cancer burden worldwide, and remains the second leading cause of cancer-related death. Due to its insidious nature, presentation is usually late and often carries a poor prognosis. Despite having improved treatment modalities over the last decade, for most patients only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and its signaling pathways, offers the hope of clinically significant promising advances for selected groups of patients. Patients with Her-2 overexpression or amplification have experienced benefit from the integration of monoclonal antibodies such as trastuzumab to the standard chemotherapy. Additionally, drugs targeting angiogenesis (bevacizumab, sorafenib, sunitinib) are under investigation and other targeted agents such as mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors are in preclinical or early clinical development. Patient selection and the development of reliable biomarkers to accurately select patients most likely to benefit from these tailored therapies is now key. Future trials should focus on these advances to optimize the treatment for GC patients. This article will review recent progress and current status of targeted agents in GC.

show abstract

Gastric Cancer: Pathogenesis, Screening, and Treatment

Cited by 31 publications

References 23 publications

Hospital Authority audit of the outcome of endoscopic resection of superficial upper gastro-intestinal lesions in Hong Kong

Hospital Authority audit of the outcome of endoscopic resection of superficial upper gastro-intestinal lesions in Hong Kong

Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer

Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy

Contact Info

Product

Resources

About